Epidemiology and treatment patterns for locally advanced or metastatic urothelial carcinoma: a systematic literature review and gap analysis
Z Hepp, SN Shah, K Smoyer, P Vadagam - Journal of Managed Care & …, 2021 - jmcp.org
BACKGROUND: Several immuno-oncology (IO) agents targeting programmed death-1 or
programmed death-ligand 1 (PD-1/L1) are approved second-line therapy options for …
programmed death-ligand 1 (PD-1/L1) are approved second-line therapy options for …
Vinflunine in the treatment of advanced urothelial cancer: clinical evidence and experience
H Gerullis, F Wawroschek… - … advances in urology, 2017 - journals.sagepub.com
Vinflunine (VFL) has been approved in Europe for second-line treatment of metastatic and
advanced urothelial cancer after failure of platin-containing therapy. Since approval, the …
advanced urothelial cancer after failure of platin-containing therapy. Since approval, the …
Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract: an evidence-based review of safety, efficacy, and place in …
SC Brousell, JJ Fantony, MG Van Noord… - Core …, 2018 - Taylor & Francis
Background: A systematic review and meta-analysis of the use of systemic vinflunine (VIN)
in the treatment of urothelial carcinoma (UC) was performed to evaluate its efficacy based on …
in the treatment of urothelial carcinoma (UC) was performed to evaluate its efficacy based on …
From clinical trials to the front line: Vinflunine for treatment of urothelial cell carcinoma at the National Cancer Institute of Naples
G Facchini, C Della Pepa, C Cavaliere… - Frontiers in …, 2016 - frontiersin.org
Background: The efficacy of Vinflunine, after failure of platinum-based chemotherapy in
patients with metastatic or recurrent Transitional Cell Cancer of the Urothelial Tract, TCCU …
patients with metastatic or recurrent Transitional Cell Cancer of the Urothelial Tract, TCCU …
Better characterization of vinflunine pharmacokinetics variability and exposure/toxicity relationship to improve its use: Analyses from 18 trials
A Schmitt, L Nguyen, G Zorza, P Ferré… - British journal of …, 2018 - Wiley Online Library
Aims Vinflunine is a novel tubulin‐targeted inhibitor indicated as a single agent for the
treatment of bladder cancers after failure of prior platinum‐based therapy. Its …
treatment of bladder cancers after failure of prior platinum‐based therapy. Its …
Bedeutung der Insulinrezeptor-ß-subunit für die Tumorbiologie des muskelinfiltrierenden Harnblasenkarzinoms vor dem Hintergrund Diabetes-assoziierter …
LC Exner - 2021 - ub01.uni-tuebingen.de
Ziel dieser Arbeit war die Analyse von Harnblasentumorpatienten mit und ohne Diabetes
mellitus Erkrankung. Die Analyse erfolgte im ersten Teil anhand klinischer Parameter. Im …
mellitus Erkrankung. Die Analyse erfolgte im ersten Teil anhand klinischer Parameter. Im …
Discovery of a small molecule TUBB3/βIII-tubulin modulator in lung cancer
FCL Kao - 2016 - unsworks.unsw.edu.au
Abstract Non-small Cell Lung Cancer (NSCLC) survival rates are dismal and chemotherapy
resistance is a significant clinical problem. 13111-tubulin (encoded by TUBB3 gene) is …
resistance is a significant clinical problem. 13111-tubulin (encoded by TUBB3 gene) is …
[引用][C] Bedeutung der Insulinrezeptor-ß-subunit für die Tumorbiologie des muskelinfiltrierenden Harnblasenkarzinoms vor dem Hintergrund Diabetes-assoziierter …
LC Exner - Dissertation, Tübingen, Universität …